ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 805,11
1,48%
DAX
18 518,03
-0,44%
Brent Oil
83,47
-1,03%
Bitcoin
64 380,31
-0,73%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
14/03/202412h00Business WireIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024NASDAQ:SMMTSummit Therapeutics Inc
05/03/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
05/03/202413h00Business WireSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
20/02/202413h55Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SMMTSummit Therapeutics Inc
20/02/202413h32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SMMTSummit Therapeutics Inc
20/02/202413h00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023NASDAQ:SMMTSummit Therapeutics Inc
14/02/202422h35Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
14/02/202416h29Business WireSummit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024NASDAQ:SMMTSummit Therapeutics Inc
14/02/202413h00Business WireSummit Therapeutics to Host Fourth Quarter & Full Year 2023NASDAQ:SMMTSummit Therapeutics Inc
07/02/202413h00Business WireSummit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences ConferenceNASDAQ:SMMTSummit Therapeutics Inc
08/01/202415h00Business WireSummit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
04/01/202422h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
03/01/202413h30Business WireSummit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
07/11/202314h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SMMTSummit Therapeutics Inc
07/11/202313h00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023NASDAQ:SMMTSummit Therapeutics Inc
02/11/202321h41Business WireLaura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical DevelopmentNASDAQ:SMMTSummit Therapeutics Inc
31/10/202313h00Business WireIvonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023NASDAQ:SMMTSummit Therapeutics Inc
26/10/202314h00Business WireSummit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023NASDAQ:SMMTSummit Therapeutics Inc
19/10/202314h00Business WireH. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical DevelopmentNASDAQ:SMMTSummit Therapeutics Inc
16/10/202313h00Business WireSummit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating OfficerNASDAQ:SMMTSummit Therapeutics Inc
19/09/202321h40Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SMMTSummit Therapeutics Inc
08/09/202322h08Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SMMTSummit Therapeutics Inc
09/08/202313h00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023NASDAQ:SMMTSummit Therapeutics Inc
02/08/202314h00Business WireSummit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023NASDAQ:SMMTSummit Therapeutics Inc
05/06/202314h44Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SMMTSummit Therapeutics Inc
04/06/202314h00Business WirePromising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023NASDAQ:SMMTSummit Therapeutics Inc
01/06/202313h30Business WireIvonescimab Updated Data to be Featured at ASCO 2023NASDAQ:SMMTSummit Therapeutics Inc
11/05/202322h05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SMMTSummit Therapeutics Inc
11/05/202313h30Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023NASDAQ:SMMTSummit Therapeutics Inc
09/05/202313h30Business WireSummit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)NASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

SPI
SP500
S&P 500
EU
DG
Vinci
NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
EU
VK
Vallourec
EU
VIV
Vivendi
EU
EN
Bouygues
COIN
ETHUSD
Ethereum
EU
ACA
Credit Agricole
EU
RNO
Renault
EU
ML
Michelin
EU
AF
Air FranceKLM
EU
GLE
Societe Generale
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés